Francesca Bruce on Muck Rack

Francesca Bruce

Verified
As seen in: Citeline, Scrip, The Pink Sheet, Generics Bulletin, HBW Insight, In Vivo, Medtech Insight
I am a senior writer at the Pink Sheet, all views expressed are my own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Francesca

Contact Francesca, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Francesca Bruce’s Biography

Read Full Bio →

Francesca covers a range of policy and regulatory developments in Europe, with a focus on pricing and reimbursement and market access. In her role at Scrip she has also covered key emerging markets in Latin America, concentrating on Brazil, Mexico and Argentina.

Articles

European Commission Will Accelerate Wastewater Directive Implementing Act To Give Cost Clarity

|
By Francesca Bruce Verified
| The Pink Sheet Verified
The European Parliament has thrown its weight behind calls for the European Commission to think again about extended producer responsibilities in the revised Urban Wastewater Treatment Directive that will be burdensome for the pharmaceutical industry. The European Commission plans to give guidance on how EU member states can implement the revised Urban Wastewater Treatment Directive without causing medicines shortages.
Open in Who Shared Issue with article?

A Milestone And A Warning: EU’s First JCA Exposes Gaps Before 2028 Rare-Disease Deadline

|
By Francesca Bruce Verified
| Citeline Verified
The first ever EU-level joint clinical assessment report marks a major milestone for the EU market access environment. The first-ever EU-level joint clinical assessment (JCA), on Ipsen’s rare pediatric cancer drug Ojemda (tovorafenib), marks an important milestone for the EU’s market access environment. Pharma industry experts say it also offers important lessons on how the system needs to be improved, especially when it comes to rare disease drugs.
Open in Who Shared Issue with article?

What Is Next For Ipsen’s Ojemda After The First Ever EU JCA?

|
By Francesca Bruce Verified
| The Pink Sheet Verified
Ipsen’s Ojemda has already been launched in two EU markets and the company is now ready to work with other member states to discuss the first ever joint clinical assessment report and get the rare pediatric cancer drug to patients.
Open in Who Shared Issue with article?
See all 1,010 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified